(Q38179461)

30 August 2017

Therapeutic targets for rheumatoid arthritis: Progress and promises (English)

1 reference

30 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Abdullah Alghasham

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

20 January 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

77-94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

Are biological targets the final goal for rheumatoid arthritis therapy?

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Citrullinated fibronectin inhibits apoptosis and promotes the secretion of pro-inflammatory cytokines in fibroblast-like synoviocytes in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Targeting TNF superfamily members for therapeutic intervention in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Update on Targets of Biologic Therapies for Rheumatoid Arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Rheumatoid arthritis and tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Rheumatoid arthritis therapy: advances from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The problem of choice: current biologic agents and future prospects in RA.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Cytokine signal regulation and autoimmune disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

What's new in our understanding of the role of adipokines in rheumatic diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

RAGE-mediated cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

HMGB1: a signal of necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Specific siRNA targeting receptor for advanced glycation end products (RAGE) decreases proliferation in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Green tea polyphenol epigallocatechin-3-gallate inhibits advanced glycation end product-induced expression of tumor necrosis factor-alpha and matrix metalloproteinase-13 in human chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

MAPKs and their relevance to arthritis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Emerging targets of biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The p38 MAPK Pathway in Rheumatoid Arthritis: A Sideways Look

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as o

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Inhibiting inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-7 levels in synovial fluid increase with age and MMP-1 levels decrease with progression of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-7 in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Progression to rheumatoid arthritis in early inflammatory arthritis is associated with low IL-7 serum levels

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Human CD4(+) effector T lymphocytes generated upon TCR engagement with self-peptides respond defectively to IL-7 in their transition to memory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-18 gene polymorphisms and rheumatoid arthritis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Cellular targets of interleukin-18 in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-18 and the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Regulation and functions of the IL-10 family of cytokines in inflammation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Emerging role of interleukin-22 in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-19 as a potential therapeutic in autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Isolation and characterization of human interleukin-10-secreting T cells from peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

LILRA5 is expressed by synovial tissue macrophages in rheumatoid arthritis, selectively induces pro-inflammatory cytokines and IL-10 and is regulated by TNF-alpha, IL-10 and IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-19 blockade attenuates collagen-induced arthritis in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Induction of interleukin-19 and interleukin-22 after cardiac surgery with cardiopulmonary bypass.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Structural basis for receptor sharing and activation by interleukin-20 receptor-2 (IL-20R2) binding cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-17/Th17 mediated synovial inflammation is IL-22 independent

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Functional role of IL-22 in psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-32 with potential insights into rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-32-induced thymic stromal lymphopoietin plays a critical role in macrophage differentiation through the activation of caspase-1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-32 aggravates synovial inflammation and bone destruction and increases synovial natural killer cells in experimental arthritis models

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IL-32, a proinflammatory cytokine in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Adipokines as emerging mediators of immune response and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Visfatin and adiponectin as novel markers for evaluation of metabolic disturbance in recently diagnosed rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Adiponectin isoforms: a potential therapeutic target in rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Adiponectin and leptin induce VCAM-1 expression in human and murine chondrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Leptin produced by joint white adipose tissue induces cartilage degradation via upregulation and activation of matrix metalloproteinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The contribution of adipose tissue and adipokines to inflammation in joint diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The role of leptin in innate and adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Further evidence for leptin involvement in cartilage homeostases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Epigenetic regulation of leptin affects MMP-13 expression in osteoarthritic chondrocytes: possible molecular target for osteoarthritis therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Adiponectin: a biomarker for rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

An inflammatory cascade leading to hyperresistinemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

B effector cells in rheumatoid arthritis and experimental arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

AGE and their receptor RAGE in systemic autoimmune diseases: an inflammation propagating factor contributing to accelerated atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Soluble forms of RAGE in human diseases: clinical and therapeutical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The receptor RAGE: Bridging inflammation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Kinase inhibitors: a new class of antirheumatic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Role of the NF-kappaB axis in immune modulation of osteoclasts and bone loss

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Negative regulation of NF-κB and its involvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Expression and regulation of inducible IkappaB kinase (IKK-i) in human fibroblast-like synoviocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Inhibitor of nuclear factor kappaB kinase beta is a key regulator of synovial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Regulatory immune cell subsets in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

B cells as effectors and regulators of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Review: Immune cells and mediators of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Natural autoantibodies and associated B cells in immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Glycoprotein 96 perpetuates the persistent inflammation of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Characterization of the Interleukin (IL)-6 Inhibitor IL-6-RFP: fused receptor domains act as high affinity cytokine-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Effects of a novel tylophorine analog on collagen-induced arthritis through inhibition of the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Immunity 12 years after alemtuzumab in RA: CD5⁺ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Effects of RWJ 67657, a p38 mitogen activated protein kinase (MAPK) inhibitor, on the production of inflammatory mediators by rheumatoid synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A multitude of kinases--which are the best targets in treating rheumatoid arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

ERK-dependent T cell receptor threshold calibration in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Periodic, partial inhibition of IkappaB Kinase beta-mediated signaling yields therapeutic benefit in preclinical models of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Regulation of synovial cell apoptosis by proteasome inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Jak inhibitor ; possibility and mechanism as a new disease modifying anti-rheumatic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Prospective new biological therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

A biological therapy to osteoarthritis treatment using platelet-rich plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Biologics in development for rheumatoid arthritis: relevance to osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Biologic agents in osteoarthritis: hopes and disappointments

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

TNF inhibition for ophthalmic indications: current status and outlook

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

The anti-CD20 antibody rituximab reduces the Th17 cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2013.873413

10.3109/08916934.2013.873413

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24437572%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference